BSE - Free Realtime Quote INR

Kilitch Drugs (India) Limited (KILITCH.BO)

Compare
342.25
-2.30
(-0.67%)
As of 12:43:03 PM GMT+5:30. Market Open.
Loading Chart for KILITCH.BO
DELL
  • Previous Close 344.55
  • Open 346.95
  • Bid 340.05 x --
  • Ask 342.35 x --
  • Day's Range 340.10 - 355.20
  • 52 Week Range 298.45 - 469.85
  • Volume 67
  • Avg. Volume 2,617
  • Market Cap (intraday) 5.504B
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) 33.33
  • EPS (TTM) 10.27
  • Earnings Date Feb 6, 2025 - Feb 10, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Sep 20, 2019
  • 1y Target Est --

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, antifungals, corticosteroids, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, soft gelatin capsules, dry syrup, gripe water, and oral gel, powder, and liquid in the cardiovascular and anti-diabetics areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, and ROIVIT; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, creams, lotions, liquids, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

www.kilitch.com

168

Full Time Employees

March 31

Fiscal Year Ends

Recent News: KILITCH.BO

View More

Performance Overview: KILITCH.BO

Trailing total returns as of 1/21/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

KILITCH.BO
7.97%
S&P BSE SENSEX
2.04%

1-Year Return

KILITCH.BO
13.15%
S&P BSE SENSEX
6.93%

3-Year Return

KILITCH.BO
43.50%
S&P BSE SENSEX
28.90%

5-Year Return

KILITCH.BO
164.90%
S&P BSE SENSEX
84.57%

Compare To: KILITCH.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: KILITCH.BO

View More

Valuation Measures

Annual
As of 1/20/2025
  • Market Cap

    5.54B

  • Enterprise Value

    5.28B

  • Trailing P/E

    33.52

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.52

  • Price/Book (mrq)

    2.93

  • Enterprise Value/Revenue

    3.37

  • Enterprise Value/EBITDA

    18.66

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.32%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.51B

  • Net Income Avi to Common (ttm)

    125.85M

  • Diluted EPS (ttm)

    10.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    690.71M

  • Total Debt/Equity (mrq)

    18.01%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: KILITCH.BO

View More

Company Insights: KILITCH.BO

Research Reports: KILITCH.BO

View More

People Also Watch